| |
Predialysis (n = 56)
|
Incident (< 1 year) (n = 50)
|
Prevalent (1–3 years) (n = 57)
|
Prevalent (> 3 years) (n = 62)
|
p value
|
---|
| |
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
| |
---|
Gender
|
Male
|
37
|
66.1
|
33
|
66.0
|
35
|
61.4
|
39
|
62.9
| |
Female
|
19
|
33.9
|
17
|
34.0
|
22
|
38.6
|
23
|
37.1
|
0.94
|
Age group
|
65–69
|
20
|
35.7
|
20
|
40.0
|
21
|
36.8
|
26
|
41.9
| |
70–74
|
11
|
19.6
|
16
|
32.0
|
15
|
26.3
|
22
|
35.5
| |
75–79
|
13
|
23.2
|
6
|
12.0
|
16
|
28.1
|
10
|
16.1
|
0.13
|
80+
|
12
|
21.4
|
8
|
16.0
|
5
|
8.8
|
4
|
6.5
| |
Ethnicity (self reported)
|
European
|
30
|
53.6
|
19
|
38.0
|
23
|
40.4
|
24
|
38.7
| |
Māori
|
10
|
17.9
|
10
|
20.0
|
18
|
31.6
|
12
|
19.4
| |
Pacific
|
6
|
10.7
|
17
|
34.0
|
10
|
17.5
|
19
|
30.6
|
0.06
|
Other
|
10
|
17.9
|
4
|
8.0
|
6
|
10.5
|
7
|
11.3
| |
Comorbiditiesa
|
Cardiovascular disease
|
36
|
64.3
|
33
|
66.0
|
38
|
66.7
|
44
|
71.0
|
0.88
|
Cerebrovascular disease
|
4
|
7.1
|
3
|
6.0
|
5
|
8.8
|
5
|
8.1
|
0.97
|
Peripheral vascular disease
|
13
|
23.2
|
7
|
14.0
|
11
|
19.3
|
14
|
22.6
|
0.63
|
Diabetes mellitus
|
27
|
48.2
|
29
|
58.0
|
32
|
56.1
|
32
|
51.6
|
0.74
|
Respiratory disease
|
16
|
28.6
|
10
|
20.0
|
9
|
15.8
|
14
|
22.6
|
0.43
|
cancer (other than skin cancer)
|
8
|
14.3
|
11
|
22.0
|
8
|
14.0
|
11
|
17.7
|
0.67
|
Musculoskeletal
|
18
|
32.1
|
14
|
28.0
|
14
|
24.6
|
22
|
35.5
|
0.60
|
Other
|
36
|
64.3
|
30
|
60.0
|
37
|
64.9
|
37
|
59.7
|
0.91
|
Comorbidity count
|
0 to 2
|
24
|
42.9
|
23
|
46.0
|
29
|
50.9
|
28
|
45.2
| |
3 to 6
|
32
|
57.1
|
27
|
54.0
|
28
|
49.1
|
34
|
54.8
|
0.85
|
Cause of ESKD
|
Glomerulonephritis
|
8
|
14.3
|
9
|
18.0
|
7
|
12.3
|
14
|
22.6
| |
Hypertension
|
10
|
17.9
|
7
|
14.0
|
12
|
21.1
|
9
|
14.5
| |
Polycystic kidney
|
2
|
3.6
|
1
|
2.0
|
4
|
7.0
|
5
|
8.1
| |
Diabetes mellitus
|
20
|
35.7
|
22
|
44.0
|
27
|
47.4
|
23
|
37.1
|
0.55
|
Other
|
16
|
28.6
|
11
|
22.0
|
7
|
12.3
|
11
|
17.7
| |
- amultiple comorbidities possible